Keytruda Improves Survival as Second-Line Treatment for Esophageal Cancer

Second-line treatment with pembrolizumab (Keytruda, Merck) reduced the risk of death by 31% in patients with advanced esophageal cancer compared with chemotherapy, according to new data from the KEYNOTE-181 phase 3 trial.
https://www.specialtypharmacytimes.com/news/keytruda-improves-survival-as-second-line-treatment-for-esophageal-cancer

AUDIENCES

Caregivers
Friends and Family
General Public
Medical Profession
Patients
Survivors

SUBJECTS

Post Surgical

Disclaimer: This information is for educational purposes only, It is not to diagnose or treat your disease. If you do use the information contained on this web site without the approval of a health professional, you are prescribing for yourself, which is your constitutional right, but the author(s) and webmaster assume no responsibility

© 2024 Esophageal Cancer Education Foundation- by domino